Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abametapir
- Development stage
- Approved
- Lead developer
- Pelthos Therapeutics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Abametapir is a topical small molecule pediculicide used for the treatment of head lice infestation in patients six months of age and older. It acts as a metalloproteinase inhibitor targeting louse metalloproteinases that are essential for egg development and survival. By inhibiting these enzymes through chelation of metal cations, abametapir disrupts the life cycle of lice at all stages—including eggs—making it effective with a single application. This mechanism distinguishes it from other treatments that often require multiple doses due to limited ovicidal activity. Abametapir is metabolized primarily by CYP1A2 to active metabolites and can inhibit cytochrome P450 enzymes (CYP3A4, CYP2B6, CYP1A2) in vitro[1][3][4][7].
- Brand names
- Xeglyze
- Other names
- abametapir
02
Targets
Pediculus humanus capitis
Beyond the preview
Go deeper on abametapir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abametapir.